RxDoctor Payments Data

John Kaufman, MD

Vascular & Interventional Radiology · Portland, ORNPI 1992711584

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $18,230 of the $29,179 with a category attached, or 62.5%. Cook Incorporated accounts for 68.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $11,921 and has fallen 99.4% since, to $74 in 2025.

$29,179in general payments, 2019–2025

Across 42 payments — averaging $694.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Incorporated$20K
  • Shape Memory Medical Inc.$4K
  • Canon Medical Systems USA, Inc.$1K
  • Covidien LP$1K
  • Cook Medical LLC$1K
  • Bayer$876
  • plus $122 from 2 others
$45,900in research payments, 2019–2025

Across 19 payments — averaging $2415.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • W. L. Gore & Associates, Inc.$40K
  • Cook Research Incorporated$6K
$4,200in ownership & investment interests, 2019–2025

Across 2 payments — averaging $2100.00 each. An ownership or investment interest held by the physician or an immediate family member.

  • Shape Memory Medical Inc.$4K

What the payments were for

  • Royalty or licence$1,3985%
  • Consulting fees$6,64623%
  • Speaking & faculty fees$18,23062%
  • Travel & lodging$1,8926%
  • Food & beverage$1,0133%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,179 in reported general payments places this provider in the 85th percentile of 73 vascular & interventional radiology providers in Oregon.

See all vascular & interventional radiology providers in Oregon

Medicare billing

Part B allowed, 2024
$23,249
Medicare patients
73
Services billed
215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisone12$16

Paid to pharmacies, not to this prescriber.

Other vascular & interventional radiology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →